0 Beoordelingen
ID

22331

Beschrijving

A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, This form is to be performed in Treatment Phase. Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Link

https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Trefwoorden

Versies (1)
  1. 30-05-17 30-05-17 -
Geüploaded op

30 mei 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

  • Nieuwste
  • Oudste
  • Populair
  • Nieuwste
    • Nieuwste
    • Oudste
    • Populair

    Geen commentaren

    U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    Engels

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    1 Formulieren  
    Concomitant Medication
    Beschrijving

    Concomitant Medication

    Alias
    UMLS CUI-1
    C2347852
    Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
    Beschrijving

    Concomitant agent

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C2347852
    Concomitant Medication Changes
    Beschrijving

    Concomitant Medication Changes

    Alias
    UMLS CUI-1
    C2347852
    Drug name (Trade Name preferred)
    Beschrijving

    Drug name

    Datatype

    text

    Alias
    UMLS CUI [1]
    C0013227
    SINGLE Dose/ Unit (e.g. 500mg)
    Beschrijving

    Single dose/Unit

    Datatype

    float

    Alias
    UMLS CUI [1,1]
    C2826257
    UMLS CUI [1,2]
    C1960417
    Frequency of this Dose (e.g. BID PRN)
    Beschrijving

    Frequency

    Datatype

    text

    Alias
    UMLS CUI [1]
    C3476109
    Route
    Beschrijving

    Concomitant Medication Route of Administration

    Datatype

    text

    Alias
    UMLS CUI [1]
    C2826730
    Indication
    Beschrijving

    Indication

    Datatype

    text

    Alias
    UMLS CUI [1,1]
    C2347852
    UMLS CUI [1,2]
    C3146298
    Start Date/Time
    Beschrijving

    Start Date Time

    Datatype

    datetime

    Alias
    UMLS CUI [1]
    C2827019
    End Date/Time
    Beschrijving

    Stop Date

    Datatype

    datetime

    Alias
    UMLS CUI [1,1]
    C0013227
    UMLS CUI [1,2]
    C0806020
    UMLS CUI [2,1]
    C0013227
    UMLS CUI [2,2]
    C1522314
    Continuing at end of Study?
    Beschrijving

    Continuing at end of study

    Datatype

    boolean

    Alias
    UMLS CUI [1]
    C1553904
    Terug naar het begin van de pagina

    Similar models

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    1 Formulieren
    Name
    Type
    Description | Question | Decode (Coded Value)
    Datatype
    Alias
    Item Group
    Concomitant Medication
    C2347852 (UMLS CUI-1)
    Concomitant agent
    Item
    Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
    boolean
    C2347852 (UMLS CUI [1])
    Item Group
    Concomitant Medication Changes
    C2347852 (UMLS CUI-1)
    Drug name
    Item
    Drug name (Trade Name preferred)
    text
    C0013227 (UMLS CUI [1])
    Single dose/Unit
    Item
    SINGLE Dose/ Unit (e.g. 500mg)
    float
    C2826257 (UMLS CUI [1,1])
    C1960417 (UMLS CUI [1,2])
    Frequency
    Item
    Frequency of this Dose (e.g. BID PRN)
    text
    C3476109 (UMLS CUI [1])
    Concomitant Medication Route of Administration
    Item
    Route
    text
    C2826730 (UMLS CUI [1])
    Indication
    Item
    Indication
    text
    C2347852 (UMLS CUI [1,1])
    C3146298 (UMLS CUI [1,2])
    Start Date Time
    Item
    Start Date/Time
    datetime
    C2827019 (UMLS CUI [1])
    Stop Date
    Item
    End Date/Time
    datetime
    C0013227 (UMLS CUI [1,1])
    C0806020 (UMLS CUI [1,2])
    C0013227 (UMLS CUI [2,1])
    C1522314 (UMLS CUI [2,2])
    Continuing at end of study
    Item
    Continuing at end of Study?
    boolean
    C1553904 (UMLS CUI [1])
    Terug naar het begin van de pagina 

    Help

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial